Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II

Name: Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
License: Public Domain

Tianjin Medical University Cancer Institute and Hospital

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

esophageal-squamous-cell-carcinoma

esophageal squamous cell carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 674893
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.